Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: AIDS Vaccine 2012

Open Access Open Badges Poster presentation

Recombinant attenuated M.tuberculosis-SIVgag(rAMtb-gag) vaccination primes for SIV-specific CD8 T cell response that are boosted by Ad5-SIVgag in mice

U Kadayam Ranganathan1*, M Larsen1, K Abel2, WR Jacobs3 and G Fennelly1

  • * Corresponding author: U Kadayam Ranganathan

Author Affiliations

1 Albert Einstein College of Medicine, Bronx, NY, USA

2 Dept of Microbiology and Immunology, UNC School of Medicine, Chapel Hill, NC, USA

3 Howard Hughes Medical Institute, Albert Einstein College of Medicine, USA

For all author emails, please log on.

Retrovirology 2012, 9(Suppl 2):P263  doi:10.1186/1742-4690-9-S2-P263

The electronic version of this article is the complete one and can be found online at:

Published:13 September 2012

© 2012 Kadayam Ranganathan et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


BCG vaccination is no longer advised in children with HIV infection due to the risk of disseminated disease. As a safer alternative to BCG and as a vector for HIV vaccination, we developed a novel vaccine based on an M. tb mutant that contains genetic deletions in essential nutrients (pantothenate and Leucine) and immune modulating pathways (ΔSecA2).


To optimize T cell responses against SIV after vaccine priming with a candidate ΔPanCD ΔLeuCD ΔSecA2 M. tuberculosis (mc26208) strain expressing the codon optimized SIVmac239 gag (designated mc26435), we boosted with Adenovirus 5 expressing SIV gag in 5-6 week old C57/BL6 mice. Lymphocytes from blood, lung and spleen cells were collected 2 and 6 weeks after boosting to detect SIV gag-specific CD8 T cells by tetrameric staining for the H-2Db haplotype AL11 tetramer (AAVKNWMTQTL) and flow cytometric analysis.


To determine the relative priming ability of rAMtb, rBCG, DNA vaccine, and rAd expressing the relevant Gag sequence, several groups of mice (5 per group) were immunized according to various prime/boost schedules. In general, Ad5gag boosting enhanced T cell responses after either mc26435 or BCG-SIV priming compare to mycobacterial priming alone.


mc26435, mc26206 (ΔPanCD ΔLeuCD) expressing SIV gag and rBCG boosted with Ad5gag had comparable response in the lung at 2 wks (2-6%). Although the most frequent SIV-specific CD8+ T cell responses were observed after Ad5gag boosting among splenocytes (7%) in BCG primed mice, significant responses (3-6% of all CD8+ T cells) were observed after Ad5gag boosting in mice primed with either rAMtb-gag strain mc26435 or mc26206. These results suggest that SIV-specific T cell responses after rAMtb-gag priming can be boosted by the Ad5gag. rAMtb-HIV is a safe candidate vaccine for infants that is likely to prime for T cell responses against both HIV and TB.